SynthesisFrontiers in immunology2026
CT-based radiomics in predicting the efficacy of preoperative neoadjuvant chemoimmunotherapy for non-small cell lung cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Adjuvant-Phase Dilemma After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC: Evidence and Response-Guided Strategies.Cancers · 2026Review
- Robotic Thoracic Surgery After Neoadjuvant Chemo-Immunotherapy for NSCLC: A Narrative Review.Cancers · 2026Review
- Radiomics in Lung Cancer Imaging: A Narrative Review of Current Evidence.Journal of imaging · 2026Review
- Predictive Value of Circulating Tumor Cells in Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer.Thoracic cancer · 2026Article
- Artificial Intelligence Tools in Precision Lung Cancer Care: From Early Detection to Clinical Decision Support.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Neoadjuvant chemoimmunotherapy significantly improves surgical resection rates, major pathological response rates (MPR), pathological complete response rates (pCR), and survival rates in patients with resectable NSCLC. Through systematic reviews and meta-analyses, we examined the diagnostic value of CT-based predictive models in predicting neoadjuvant chemoimmunotherapy treatment outcomes for NSCLC. Method: PubMed, Embase, Web of Science databases, China National Knowledge Infrastructure, and Wanfang were systematically searched up to January 12, 2026. To assess study risk of bias and quality, we employed the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool and the Radiomics Quality Score version 2.0(RQS). Diagnostic accuracy of radiomics for detecting neoadjuvant chemoimmunotherapy pathological response in NSCLC patients was evaluated by calculating the area under the curve (AUC), sensitivity, specificity, and accuracy for each study. Results: The meta-analysis analyzed 17 studies with 4,510 individual subjects. The pooled AUC, sensitivity, and specificity of internal validation models were 0.81, 0.79, and 0.69, respectively. The pooled AUC, sensitivity, and specificity of external validation models were 0.80, 0.75, and 0.73, accordingly. Subgroup analyses revealed that models using deep learning (DL) algorithms demonstrated superior sensitivity (internal: 0.79, 95% CI: 0.73-0.85; external: 0.77, 95% CI: 0.72-0.82) and specificity (internal: 0.79, 95% CI: 0.74-0.85; external: 0.73, 95% CI: 0.68-0.78) compared to those using machine learning (ML). Models predicting MPR exhibited higher sensitivity in internal validation (0.82, 95% CI: 0.77-0.86), while showing higher specificity in external validation (0.76, 95% CI: 0.72-0.81). In contrast, models predicting pCR demonstrated the opposite pattern. Features selected using the intraclass correlation coefficient (ICC) demonstrated significantly higher pooled sensitivity (internal: 0.85, 95% CI: 0.80-0.89; external: 0.81, 95% CI: 0.76-0.87) and specificity (internal: 0.70, 95% CI: 0.63-0.78; external: 0.77, 95% CI: 0.71-0.82) compared to non-ICC-selected features. When stratified by the median Radiomics Quality Score (RQS ≥ 41.07%), higher-scoring studies were associated with lower pooled sensitivity (internal: 0.78, 95% CI: 0.73-0.84; external: 0.71, 95% CI: 0.66-0.76) but a trend toward higher specificity. Finally, models based on two-dimensional regions of interest (2D ROI) demonstrated higher pooled sensitivity (internal: 0.86, 95% CI: 0.80-0.92; external: 0.87, 95% CI: 0.79-0.96) and specificity in external validation (0.80, 95% CI: 0.68-0.91). Conclusion: Due to its good diagnostic accuracy, widespread use, and low cost, CT-based radiomics can be used to predict the efficacy of neoadjuvant chemoimmunotherapy in NSCLC preoperatively. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier (CRD420251174128).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.